SOA Wealth Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-150
| Closed | -$2.24K | – | 878 |
|
|
2024
Q3 | $2.24K | Hold |
150
| – | – | ﹤0.01% | 660 |
|
|
2024
Q2 | $2.03K | Hold |
150
| – | – | ﹤0.01% | 672 |
|
|
2024
Q1 | $2.49K | Hold |
150
| – | – | ﹤0.01% | 682 |
|
|
2023
Q4 | $2.02K | Hold |
150
| – | – | ﹤0.01% | 697 |
|
|
2023
Q3 | $1.64K | Hold |
150
| – | – | ﹤0.01% | 733 |
|
|
2023
Q2 | $1.94K | Hold |
150
| – | – | ﹤0.01% | 727 |
|
|
2023
Q1 | $1.8K | Hold |
150
| – | – | ﹤0.01% | 742 |
|
|
2022
Q4 | $2.06K | Hold |
150
| – | – | ﹤0.01% | 735 |
|
|
2022
Q3 | $2K | Hold |
150
| – | – | ﹤0.01% | 700 |
|
|
2022
Q2 | $2K | Hold |
150
| – | – | ﹤0.01% | 689 |
|
|
2022
Q1 | $2K | Buy |
150
+11
| +8% | +$147 | ﹤0.01% | 787 |
|
|
2021
Q4 | $3K | Hold |
139
| – | – | ﹤0.01% | 719 |
|
|
2021
Q3 | $4K | Hold |
139
| – | – | ﹤0.01% | 704 |
|
|
2021
Q2 | $4K | Hold |
139
| – | – | ﹤0.01% | 685 |
|
|
2021
Q1 | $4K | Hold |
139
| – | – | ﹤0.01% | 642 |
|
|
2020
Q4 | $4K | Buy |
+139
| New | +$4K | ﹤0.01% | 625 |
|